Daiichi licenses Japanese rights to Kite's CART candidate axicabtagene ciloleucel
Executive Summary
Kite Pharma Inc. granted Daiichi Sankyo Co. Ltd. rights to develop and sell its lead CART candidate axicabtagene ciloleucel in Japan for B-cell lymphomas and leukemias.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice